Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193080 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL13076801 | 0.81 | LMNA (0.46) | ALDH1A1KMT2AMEN1GAATSHR | |
| SCHEMBL4101227 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL13077868 | 0.79 | LMNA (0.41) | ALDH1A1KMT2AMEN1GAATSHR | |
| SCHEMBL17158265 | 0.78 | KMT2A (0.48) | ALDH1A1KMT2AMEN1GAATSHR | |
| SCHEMBL17158194 | 0.77 | KMT2A (0.48) | ALDH1A1KMT2AMEN1GAATSHR | |
| SCHEMBL13888874 | 0.77 | MEN1 (0.51) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL17158232 | 0.77 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL2570325 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1POLBGAA | |
| SCHEMBL13039203 | 0.75 | HTR6 (0.46) | ALDH1A1KMT2AMEN1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | REN, AVPR1B, WNK1 | ALDH1A1 1177/4885KMT2A 2724/4885MEN1 2498/4885 |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | REN, AVPR1B, WNK1 | ALDH1A1 1177/4885KMT2A 2724/4885MEN1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.